Elanco Animal Health Incorporated Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Elanco Animal Health Incorporated (ELAN) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $13.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2021-03-01
- Elanco Animal Health Incorporated impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2018 was $13.00M, a 65.79% decline from fiscal 2017.
- Elanco Animal Health Incorporated impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2017 was $38.00M.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|
| 2018-12-31 | $13.00M 10-K · filed 2021-03-01 |
| 2017-12-31 | $38.00M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |